Developer docs
API playgroundTry for free, no card

Search company profiles

Bloom Technology

Full company profile

uuid0003wy8

Namestring
Bloom Technology
Legal namestring
Bloom Technology株式会社
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Bloom Technology Corporation is a Japanese privately-held drug discovery company founded on November 19, 2014 and headquartered in Kumamoto, Japan. The company is built around a proprietary scientific platform targeting Toxic Advanced Glycation End-products (TAGE/Glycer-AGEs), the toxic subset of advanced glycation end-products implicated in lifestyle-related diseases. Bloom Technology claims to be the first organization in the world to elucidate the chemical structure of TAGE and to generate monoclonal antibodies against this structure, and it is developing anti-TAGE antibody therapeutics aimed at diabetic retinopathy, diabetic nephropathy, and non-alcoholic steatohepatitis (NASH), with potential extension to cardiovascular disease, cancer, infertility, and Alzheimer's disease.

The company's commercial offerings comprise three lines: a core pipeline of anti-TAGE therapeutic monoclonal antibodies supported by preclinical proof-of-concept data in diabetes and NASH model mice; a TAGE blood concentration measurement service launched in September 2017 for research customers; and a small online consumer health products shop (Bloom Tech Online Shop) launched in July 2015. Its go-to-market is sales-led and research-relationship-driven: the company engages pharmaceutical companies and academic institutions through commissioned research agreements, participates in scientific conferences, and has built an extensive network of joint research agreements with Japanese universities including Kumamoto University, Niigata University of Pharmacy and Applied Life Sciences, Chiba University Graduate School of Medicine, Kanazawa Medical University, and Tokai University.

Revenue mechanics are predominantly professional services (fee-for-service testing and commissioned research) with no publicly disclosed pricing, complemented by a theoretical future stream of licensing royalties on anti-TAGE antibody IP. The company has raised approximately 330 million yen in cumulative disclosed funding across a 2018 Nissay Capital-led round (200 million yen) and a 2019 third-party share allocation (130 million yen), with stated capital of 30.5 million yen as of March 31, 2021. Headcount is 1-10 employees, no parent or controlling shareholder is disclosed, and leadership is anchored by CEO Tetsuro Yamamoto (former Kumamoto University pathology professor, M.D./Ph.D.) and Director Tamami Sakamoto.

Short descriptiontext

Bloom Technology is a Kumamoto-based Japanese biotech founded in 2014 that develops anti-TAGE monoclonal antibody therapeutics for diabetes complications and NASH, and offers TAGE blood concentration measurement services to pharmaceutical and academic research customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersKumamoto, Japan
HQ citystring
Kumamoto
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery, monoclonal antibodies, toxic-AGEs therapeutics, contract research services, biomarker measurement
Industry4 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAKADAA
Diabetes (General)
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Drug Discovery
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Commissioned Research Services
TypeProfessional Services
Description

Fee-for-service research collaborations with academic institutions and pharmaceutical companies for TAGE-related drug discovery and development.

bloom-technology.co.jp
2Contract Testing Services
TypeProfessional Services
Description

Fee-based measurement services for TAGE blood concentration analysis provided to research customers.

bloom-technology.co.jp
3Licensing Royalties
TypeLicensing Royalties
Description

Potential future revenue from licensing anti-TAGE therapeutic technologies and monoclonal antibody discoveries.

bloom-technology.co.jp
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Bloom Technology is a Japanese drug discovery company developing anti-TAGE (Toxic Advanced Glycation End-products, also known as Glycer-AGEs) monoclonal antibody therapeutics targeting diabetes complications such as retinopathy and nephropathy, as well as non-alcoholic steatohepatitis (NASH). The company also operates a commissioned TAGE blood concentration measurement service for academic and pharmaceutical research customers and runs an online shop (Bloom Tech Online Shop) for consumer health-related products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Anti-TAGE antibody administration alleviated retinal abnormalities in diabetes model mice
+1 more record
Product overview1 text field

Bloom Technology is a drug discovery company developing anti-TAGE (toxic advanced glycation end-products) therapeutics and offering contract measurement services for TAGE research. The company operates three main offerings: Toxic-AGEs measurement services for research institutions, anti-TAGE monoclonal antibody drug development targeting diabetic complications and NASH, and a consumer health products online shop.

Product and service3 records
1Toxic-AGEs Measurement Services (受託測定サービス)
CategoryContract Research Services
Description

Contract measurement service for detecting Toxic-AGEs (TAGE) concentration in blood samples, offered to academic research institutions and pharmaceutical companies for research applications such as biomarker development and lifestyle-disease studies.

2Anti-TAGE Antibody Drug Development
CategoryTherapeutic Antibody R&D
Description

Preclinical-stage therapeutic program developing proprietary monoclonal antibodies against Toxic-AGEs (TAGE/Glycer-AGEs) for treatment of diabetic retinopathy, diabetic nephropathy, and non-alcoholic steatohepatitis (NASH), pursued through joint research with academic institutions and pharmaceutical partners.

3Bloom Tech Online Shop (ブルームテックオンラインショップ)
CategoryConsumer Health Products
Description

Online sales platform offering health-related products developed or curated by the company to consumers.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Partnership for Project DI combining NAVER Cloud's AI agent technology with Bloom Technology's Locus Chain blockchain for next-generation AI integrated platform development enabling AI avatars to autonomously manage real-world and virtual activities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Partnership for Project DI, a next-generation AI integrated platform designed to expand human experience across real and virtual worlds through AI avatars.

3EOGround
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Partnership for Project DI consortium developing AI-powered digital ecosystem platform.

digitaljournal.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Partnership for Project DI consortium developing AI-powered digital ecosystem platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Partnership for Project DI consortium developing AI-powered digital ecosystem platform combining AI agents with blockchain technology.

6Kumamoto Prefecture Agricultural Research Center (熊本県農業研究センター)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2016-09-16
Description

Joint research agreement for TAGE research with agricultural research applications.

bloom-technology.co.jp
7Kumamoto University Institute of Resource Development and Analysis (熊本大学生命資源研究支援センター)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2016-06-01
Description

Joint research agreement for TAGE research development.

bloom-technology.co.jp
8Tokai University School of Agriculture (東海大学農学部)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2015-08-01
Description

Joint research agreement for germ cell preservation drug development.

bloom-technology.co.jp
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2015-06-03
Description

Funded research agreement for TAGE development research.

10Cell Science & Technology Institute (細胞科学研究所)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2015-06-01
Description

Affiliation/partnership for cell science research collaboration.

bloom-technology.co.jp
11Chiba University Graduate School of Medicine (千葉大学大学院医学部)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2015-05-01
Description

Joint research agreement for drug development collaboration.

bloom-technology.co.jp
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2015-04-01
Description

Joint research agreement for drug development, focusing on pharmaceutical development research.

13Niigata University of Pharmacy and Applied Life Sciences (新潟薬科大学)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2014-12-01
Description

Joint research agreement to test efficacy of healthcare products, focusing on Health Care product development.

bloom-technology.co.jp
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major US-based pharmaceutical innovator with an aggressive metabolic disease pipeline (including GLP-1 franchise in diabetes/obesity and active MASH programmes), establishing the competitive landscape and partnership benchmark for novel mechanisms like TAGE-targeted antibodies.

TypeBroad incumbent
Description

Top-tier Japanese pharmaceutical innovator with active R&D in metabolic and cardiovascular disease and well-established global licensing/partnering infrastructure, relevant both as a potential partner and as a comparable for biotech pipeline value in Japan.

TypeBroad incumbent
Description

Japan's largest pharmaceutical company with historical leadership in diabetes therapeutics and a global rare-disease and metabolic pipeline, frequently engaging in Japanese biotech licensing transactions that serve as a benchmark partnership template for early-stage Japanese biotechs.

TypeBroad incumbent
Description

Global leader in diabetes and obesity therapeutics with the deepest commercial franchise in the cardiometabolic indications where Bloom's anti-TAGE antibody would compete, making it a critical potential partner or competitive threat.

5Mitsubishi Tanabe Pharma
TypeBroad incumbent
Description

Major Japanese pharmaceutical company with a traditional diabetes and metabolic disease commercial footprint and frequent Japanese biotech partnering activity, providing another realistic potential acquirer or licensee for Bloom's anti-TAGE assets.

TypeDirect peer
Description

Historically the most prominent anti-AGE biopharma, developing alagebrium (ALT-711), an AGE crosslink breaker, for cardiovascular complications of diabetes. Despite being a direct scientific predecessor to Bloom's TAGE approach, Alteon illustrates the translation challenges of anti-AGE therapeutics.

7Kissei Pharmaceutical
TypeDirect peer
Description

Mid-cap Japanese specialty pharmaceutical company focused on diabetes, kidney disease, and related metabolic disorders, directly comparable in therapeutic focus to Bloom and representative of the typical Japanese partner profile for an early-stage metabolic biotech.

8Mochida Pharmaceutical
TypeRegional player
Description

Mid-sized Japanese pharmaceutical company with metabolic and specialty franchises (including diabetes adjacencies), representative of the regional partner pool where a small Japanese biotech like Bloom could secure a domestic out-licensing deal.

TypeDirect peer
Description

Clinical-stage US biopharma that developed azeliragon, a RAGE receptor antagonist for Alzheimer's disease, making it one of the closest direct comparables to Bloom Technology's anti-TAGE/anti-RAGE-pathway antibody strategy in metabolic/neurodegenerative indications.

TypeBroad incumbent
Description

Major Japanese pharmaceutical company with a substantial diabetes and metabolic disease franchise (historically including products in the diabetic complications space) and significant biopharmaceutical discovery capabilities, making it a likely potential licensing or acquisition counterparty for Bloom's pipeline.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bloom Technology

Biopharmaceutical Drug Discoverybloom-technology.co.jp

Bloom Technology is a Kumamoto-based Japanese biotech founded in 2014 that develops anti-TAGE monoclonal antibody therapeutics for diabetes complications and NASH, and offers TAGE blood concentration measurement services to pharmaceutical and academic research customers.

What Bloom Technology does

Bloom Technology Corporation is a Japanese privately-held drug discovery company founded on November 19, 2014 and headquartered in Kumamoto, Japan. The company is built around a proprietary scientific platform targeting Toxic Advanced Glycation End-products (TAGE/Glycer-AGEs), the toxic subset of advanced glycation end-products implicated in lifestyle-related diseases. Bloom Technology claims to be the first organization in the world to elucidate the chemical structure of TAGE and to generate monoclonal antibodies against this structure, and it is developing anti-TAGE antibody therapeutics aimed at diabetic retinopathy, diabetic nephropathy, and non-alcoholic steatohepatitis (NASH), with potential extension to cardiovascular disease, cancer, infertility, and Alzheimer's disease.

The company's commercial offerings comprise three lines: a core pipeline of anti-TAGE therapeutic monoclonal antibodies supported by preclinical proof-of-concept data in diabetes and NASH model mice; a TAGE blood concentration measurement service launched in September 2017 for research customers; and a small online consumer health products shop (Bloom Tech Online Shop) launched in July 2015. Its go-to-market is sales-led and research-relationship-driven: the company engages pharmaceutical companies and academic institutions through commissioned research agreements, participates in scientific conferences, and has built an extensive network of joint research agreements with Japanese universities including Kumamoto University, Niigata University of Pharmacy and Applied Life Sciences, Chiba University Graduate School of Medicine, Kanazawa Medical University, and Tokai University.

Revenue mechanics are predominantly professional services (fee-for-service testing and commissioned research) with no publicly disclosed pricing, complemented by a theoretical future stream of licensing royalties on anti-TAGE antibody IP. The company has raised approximately 330 million yen in cumulative disclosed funding across a 2018 Nissay Capital-led round (200 million yen) and a 2019 third-party share allocation (130 million yen), with stated capital of 30.5 million yen as of March 31, 2021. Headcount is 1-10 employees, no parent or controlling shareholder is disclosed, and leadership is anchored by CEO Tetsuro Yamamoto (former Kumamoto University pathology professor, M.D./Ph.D.) and Director Tamami Sakamoto.

Bloom Technology firmographics

Firmographics
Name
Bloom Technology
Legal name
Bloom Technology株式会社
Website
https://bloom-technology.co.jp
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
Bloom Technology is a Kumamoto-based Japanese biotech founded in 2014 that develops anti-TAGE monoclonal antibody therapeutics for diabetes complications and NASH, and offers TAGE blood concentration measurement services to pharmaceutical and academic research customers.
Ownership category
akta.pro rank

Bloom Technology industry classification

Industry
Product category
Biopharmaceutical Drug Discovery
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAKADAA
Diabetes (General)
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Drug discovery
  • Monoclonal antibodies
  • Toxic-AGEs therapeutics
  • Contract research services
  • Biomarker measurement

Where Bloom Technology is headquartered

Location

Headquarters

HQ city
Kumamoto
HQ country
Japan
HQ region
Asia

Offices1 record

Markets served

Bloom Technology business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Commissioned Research Services: Fee-for-service research collaborations with academic institutions and pharmaceutical companies for TAGE-related drug discovery and development.
  2. Contract Testing Services: Fee-based measurement services for TAGE blood concentration analysis provided to research customers.
  3. Licensing Royalties: Potential future revenue from licensing anti-TAGE therapeutic technologies and monoclonal antibody discoveries.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Bloom Technology product offering

Product offering

Core offering

Bloom Technology is a Japanese drug discovery company developing anti-TAGE (Toxic Advanced Glycation End-products, also known as Glycer-AGEs) monoclonal antibody therapeutics targeting diabetes complications such as retinopathy and nephropathy, as well as non-alcoholic steatohepatitis (NASH). The company also operates a commissioned TAGE blood concentration measurement service for academic and pharmaceutical research customers and runs an online shop (Bloom Tech Online Shop) for consumer health-related products.

Product overview

Bloom Technology is a drug discovery company developing anti-TAGE (toxic advanced glycation end-products) therapeutics and offering contract measurement services for TAGE research. The company operates three main offerings: Toxic-AGEs measurement services for research institutions, anti-TAGE monoclonal antibody drug development targeting diabetic complications and NASH, and a consumer health products online shop.

Differentiator

Problem solved

Functional benefit

Products and services

  • Toxic-AGEs Measurement Services (受託測定サービス) Contract measurement service for detecting Toxic-AGEs (TAGE) concentration in blood samples, offered to academic research institutions and pharmaceutical companies for research applications such as biomarker development and lifestyle-disease studies.
  • Anti-TAGE Antibody Drug Development Preclinical-stage therapeutic program developing proprietary monoclonal antibodies against Toxic-AGEs (TAGE/Glycer-AGEs) for treatment of diabetic retinopathy, diabetic nephropathy, and non-alcoholic steatohepatitis (NASH), pursued through joint research with academic institutions and pharmaceutical partners.
  • Bloom Tech Online Shop (ブルームテックオンラインショップ) Online sales platform offering health-related products developed or curated by the company to consumers.

Quantifiable outcome

  • Anti-TAGE antibody administration alleviated retinal abnormalities in diabetes model mice
  • +1 more outcomes

Companies that use Bloom Technology

Customer profile

Segments3 records

Ideal customer profiles3 records

Bloom Technology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Bloom Technology partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core, minor and major.

  • NAVER CloudcoreStrategic or Co-development Partner · 1 January 2026Partnership for Project DI combining NAVER Cloud's AI agent technology with Bloom Technology's Locus Chain blockchain for next-generation AI integrated platform development enabling AI avatars to autonomously manage real-world and virtual activities.
  • CretacoreStrategic or Co-development Partner · 1 January 2026Partnership for Project DI, a next-generation AI integrated platform designed to expand human experience across real and virtual worlds through AI avatars.
  • EOGroundcoreStrategic or Co-development Partner · 1 January 2026Partnership for Project DI consortium developing AI-powered digital ecosystem platform.
  • Lloyds CapitalcoreStrategic or Co-development Partner · 1 January 2026Partnership for Project DI consortium developing AI-powered digital ecosystem platform.
  • Nexus Core SystemscoreStrategic or Co-development Partner · 1 January 2026Partnership for Project DI consortium developing AI-powered digital ecosystem platform combining AI agents with blockchain technology.
  • Kumamoto Prefecture Agricultural Research Center (熊本県農業研究センター)minorStrategic or Co-development Partner · 16 September 2016Joint research agreement for TAGE research with agricultural research applications.
  • Kumamoto University Institute of Resource Development and Analysis (熊本大学生命資源研究支援センター)majorStrategic or Co-development Partner · 1 June 2016Joint research agreement for TAGE research development.
  • Tokai University School of Agriculture (東海大学農学部)majorStrategic or Co-development Partner · 1 August 2015Joint research agreement for germ cell preservation drug development.
  • Kanazawa Medical University Medical Research Institute (金沢医科大学総合医学研究所)majorStrategic or Co-development Partner · 3 June 2015Funded research agreement for TAGE development research.
  • Cell Science & Technology Institute (細胞科学研究所)minorStrategic or Co-development Partner · 1 June 2015Affiliation/partnership for cell science research collaboration.
  • Chiba University Graduate School of Medicine (千葉大学大学院医学部)majorStrategic or Co-development Partner · 1 May 2015Joint research agreement for drug development collaboration.
  • Kumamoto University Research Institute for Drug Discovery (熊本大学創薬研究センター)majorStrategic or Co-development Partner · 1 April 2015Joint research agreement for drug development, focusing on pharmaceutical development research.
  • Niigata University of Pharmacy and Applied Life Sciences (新潟薬科大学)majorStrategic or Co-development Partner · 1 December 2014Joint research agreement to test efficacy of healthcare products, focusing on Health Care product development.

Scale indicators2 records

Recent moves7 records

Expansion highlights4 records

Bloom Technology competitors and assessment

Company assessment

Broad incumbents

  • Eli Lilly: Major US-based pharmaceutical innovator with an aggressive metabolic disease pipeline (including GLP-1 franchise in diabetes/obesity and active MASH programmes), establishing the competitive landscape and partnership benchmark for novel mechanisms like TAGE-targeted antibodies.
  • Daiichi Sankyo: Top-tier Japanese pharmaceutical innovator with active R&D in metabolic and cardiovascular disease and well-established global licensing/partnering infrastructure, relevant both as a potential partner and as a comparable for biotech pipeline value in Japan.
  • Takeda Pharmaceutical: Japan's largest pharmaceutical company with historical leadership in diabetes therapeutics and a global rare-disease and metabolic pipeline, frequently engaging in Japanese biotech licensing transactions that serve as a benchmark partnership template for early-stage Japanese biotechs.
  • Novo Nordisk: Global leader in diabetes and obesity therapeutics with the deepest commercial franchise in the cardiometabolic indications where Bloom's anti-TAGE antibody would compete, making it a critical potential partner or competitive threat.
  • Mitsubishi Tanabe Pharma: Major Japanese pharmaceutical company with a traditional diabetes and metabolic disease commercial footprint and frequent Japanese biotech partnering activity, providing another realistic potential acquirer or licensee for Bloom's anti-TAGE assets.
  • Astellas Pharma: Major Japanese pharmaceutical company with a substantial diabetes and metabolic disease franchise (historically including products in the diabetic complications space) and significant biopharmaceutical discovery capabilities, making it a likely potential licensing or acquisition counterparty for Bloom's pipeline.

Direct peers

  • Alteon: Historically the most prominent anti-AGE biopharma, developing alagebrium (ALT-711), an AGE crosslink breaker, for cardiovascular complications of diabetes. Despite being a direct scientific predecessor to Bloom's TAGE approach, Alteon illustrates the translation challenges of anti-AGE therapeutics.
  • Kissei Pharmaceutical: Mid-cap Japanese specialty pharmaceutical company focused on diabetes, kidney disease, and related metabolic disorders, directly comparable in therapeutic focus to Bloom and representative of the typical Japanese partner profile for an early-stage metabolic biotech.
  • vTv Therapeutics: Clinical-stage US biopharma that developed azeliragon, a RAGE receptor antagonist for Alzheimer's disease, making it one of the closest direct comparables to Bloom Technology's anti-TAGE/anti-RAGE-pathway antibody strategy in metabolic/neurodegenerative indications.

Regional players

  • Mochida Pharmaceutical: Mid-sized Japanese pharmaceutical company with metabolic and specialty franchises (including diabetes adjacencies), representative of the regional partner pool where a small Japanese biotech like Bloom could secure a domestic out-licensing deal.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Bloom Technology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bloom Technology leadership team

Management profile

Number of profiles

Profiles2 records

Bloom Technology funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bloom Technology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bloom Technology

What does Bloom Technology do?

Bloom Technology is a Japanese drug discovery company developing anti-TAGE (Toxic Advanced Glycation End-products, also known as Glycer-AGEs) monoclonal antibody therapeutics targeting diabetes complications such as retinopathy and nephropathy, as well as non-alcoholic steatohepatitis (NASH). The company also operates a commissioned TAGE blood concentration measurement service for academic and pharmaceutical research customers and runs an online shop (Bloom Tech Online Shop) for consumer health-related products.

Is Bloom Technology a public or private company?

Bloom Technology is a private company. It is classified as venture growth investor backed and is currently operating.

When was Bloom Technology founded?

Bloom Technology was founded in 2014. It employs 1 to 10 people.

Where is Bloom Technology based?

Bloom Technology is headquartered in Kumamoto, Japan, in the Asia region.

How does Bloom Technology make money?

Three revenue lines are on record. Commissioned Research Services are the primary driver. The others are contract Testing Services and licensing Royalties.

Who are Bloom Technology's main competitors?

Broad incumbents on record are Eli Lilly, Daiichi Sankyo, Takeda Pharmaceutical, Novo Nordisk, Mitsubishi Tanabe Pharma and Astellas Pharma. Direct peers are Alteon, Kissei Pharmaceutical and vTv Therapeutics. Mochida Pharmaceutical is listed as a regional player.

Does Bloom Technology have an API?

No public API is recorded for Bloom Technology.

What industry is Bloom Technology in?

Bloom Technology's product category is Biopharmaceutical Drug Discovery. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 5417 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireNext-Generation Global AI Integration Platform, Project DI, LaunchesSix companies (NAVER Cloud, Bloom Technology, Creta, EOGround, Lloyds Capital, and Nexus Core Systems) officially launched Project DI, a next-generation AI integrated platform designed to expand human experience across multi-layered real and virtual worlds. The consortium signed a Memorandum of Understanding in January 2026 in Casablanca, Morocco, committing to combine their respective core technologies—NAVER Cloud's AI agent infrastructure and Bloom Technology's Locus Chain serverless blockchain—to enable AI avatars to autonomously perform real-world and virtual tasks on behalf of users. The platform架构 integrates real-world services (administration, finance, healthcare) with virtual environments (gaming, metaverse, content), positioning itself as a foundational framework for AI-powered digital ecosystems spanning B2G, B2B, B2C, and M2M use cases.Digital JournalNext-Generation Global AI Integration Platform, Project DI, LaunchesSix companies—NAVER Cloud, Bloom Technology, Creta, EOGround, Lloyds Capital, and Nexus Core Systems—signed a Memorandum of Understanding in January in Casablanca, Morocco, to jointly develop Project DI, a next-generation AI integrated platform designed to expand human experience across real and virtual worlds. The platform combines NAVER Cloud's AI agent technology with Bloom Technology's Locus Chain blockchain to enable users to delegate tasks to AI avatars that autonomously manage real-world administrative, financial, and virtual activities even while offline. The consortium positions Project DI for global scalability across B2G, B2B, B2C, and M2M use cases, aiming to become a foundation for a new era of AI-powered digital ecosystems.MorningstarNext-Generation Global AI Integration Platform, Project DI, LaunchesSix companies—NAVER Cloud, Bloom Technology, Creta, EOGround, Lloyds Capital, and Nexus Core Systems—officially launched Project DI, a next-generation AI integrated platform designed to expand human activity across both real and virtual worlds through AI avatars and personas. The consortium, which signed a joint MOU in Casablanca, Morocco this January, combines NAVER Cloud's AI agent and cloud infrastructure with Bloom Technology's Locus Chain serverless blockchain to enable AI-driven economic, administrative, and entertainment activities on behalf of users. The platform architecture spans two core pillars—DI-PoR for real-world services and DI-PoV for virtual-world experiences—all connected through a unified decentralized identity system.PRLogBloom Technology Partners Up With Myung Shin To Develop A Web3 Smart Mobility PlatformBloom Technology and Myung Shin agreed to co-develop a Web3 smart mobility platform based on Locus Chain, a public blockchain. Myung Shin, which produces EV body parts for Hyundai and Kia, plans 60,000 annual FF81 production at GM Gunsan. The partnership aims to revamp the smart mobility industry.